Gunagratinib

N/A

Report date: 2022/06/01 17:36:09
NME

Base Information

Drug NameGunagratinib
Drug Alias NameICP-192
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists +[4] 
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3 +[4] 
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Tiancheng Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Oriental HospitalBeijing Cancer HospitalWuhan Union Hospital +[6] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A